Market Cap
Novo Nordisk A/S
kr.1.012 Trillion
DKK as of Jan. 1, 2026
US$158.96 Billion
| Company | Market Cap (USD) |
|---|---|
Vertex Pharmaceuticals Incorporated
|
$115.92 B |
CSL Limited
|
$95.75 B |
Regeneron Pharmaceuticals, Inc.
|
$82.28 B |
| Marinomed Biotech AG | $70.11 B |
Samsung Biologics Co.,Ltd.
|
$54.01 B |
| Company | Market Cap (USD) |
|---|---|
Lilly
|
$968.50 B |
Johnson & Johnson
|
$499.57 B |
AbbVie
|
$405.28 B |
Roche
|
$332.12 B |
UnitedHealth Group
|
$304.72 B |
Novo Nordisk is a global healthcare company involved in the research, development, manufacture, and marketing of pharmaceutical products. It operates through two segments: Diabetes and Obesity care, providing products for insulins, GLP-1, oral antidiabetic products, obesity, and other chronic diseases; and Biopharm, offering products for haemophilia, growth disorders, and hormone replacement therapy.
Denmark
languages
Healthcare
languages
Biotechnology
Denmark Healthcare
Denmark Biotechnology
Novo Nordisk A/S has the following listings and related stock indices.
Stock: OMXC: NOVO.B
Stock: FSX: NOVC
Stock: XETR: NOVC
Stock: XETR: NOVA
Stock: FSX: NOVA
Stock: BMV: NVON
Stock: NYSE: NVO
Stock: Bovespa: N1VO34
The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.